Consumer unit to launch OTC Allegra

Share this article:
The FDA approved over-the-counter use of Sanofi-Aventis allergy drug Allegra, paving the way for launch by the French drugmaker's US consumer healthcare unit, Chattem.
The company said it plans to have OTC Allegra on pharmacy shelves by March. A Sanofi spokesperson declined to provide specifics on marketing plans.
Sanofi bought Chattem last year for $1.9 billion, and at the time CEO Chris Viehbacher hailed the acquisition for giving the firm a US marketing platform for future Rx-to-OTC switch brands, starting with Allegra.
Hanspeter Spek, Sanofi president, global operations, echoed that sentiment yesterday, stating that converting prescription medicines to OTC products is “a key growth driver for Sanofi-Aventis to become a diversified healthcare company also in the United States.”
The Allegra approval was expected, and Sanofi's increased exposure into the consumer segment, via the Chattem acquisition, will enable it to leverage the brand, Jeffries International analyst Jeff Holford, who covers Sanofi from London, told MM&M. However, beyond Allegra, Rx-to-OTC switches may not to be an immediate growth driver for the company.
“As most of Sanofi's remaining branded blockbuster drugs are for serious indications (cancer, cardiovascular disease) they do not have many more such large opportunities for OTC switches as this in the near to mid-term,” Holford wrote in an e-mail.
Plavix, a blockbuster antiplatelet drug which Sanofi co-markets with Bristol-Myers Squibb, will face generic competition in May 2012. (The companies announced that pediatric exclusivity extends their right to exclusively market Plavix another six months.) Cancer med Eloxatin, another big seller, goes off patent in August 2012.
Allegra has been on the market since 1996, and sales have decreased the last year as generic competition has arrived. The FDA approval covers the Allegra family of allergy products and is for adults and children two years and older.
Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric